Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology- United Kingdom

doi 10.3892/mco.2018.1553

Full Text

Abstract

Available in

Categories

Cancer Research

Date

January 11, 2018

Authors

Publisher

Spandidos Publications

Related search

Toxic Epidermal Necrolysis

Medical Journal Armed Forces India

English

Toxic Epidermal Necrolysis: Reply

Medical Journal Armed Forces India

English

Lyell's Toxic Epidermal Necrolysis

English

Diffuse Hemorrhagic Brain Metastases in an ALK Fusion Positive Patient on Crizotinib

Journal of Thoracic Oncology

Respiratory Medicine

English

Efficacy of Target Therapy With Crizotinib in a Patient With Alk-Positive Advanced Gastric Cancer

Siberian Journal of Oncology

Cancer Research

English

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Zonisamide

Clinical Case Reports

English

Dramatic Response to Crizotinib in an ALK-Positive Adenocarcinoma Patient With Disseminated Intravascular Coagulation

Journal of Thoracic Oncology

Respiratory Medicine

English

P2.01-109 Treatment Duration—A More Reasonable Definition to Evaluate the Efficacy of Crizotinib in ALK Positive Advanced NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Paraneoplastic Pemphigus Mimicking Toxic Epidermal Necrolysis: An Underdiagnosed Entity?

JAAD Case Reports

English